{"title":"Unlocking molecular secrets: The role of miRNAs in Parkinson's disease dynamics","authors":"Rehab A. Ismail , Mohamed Abobakr , Mostafa Mohamed , Ahmed Hussieny , Mohamed Alaa , Mostafa tarek , Shereen Saeid Elshaer","doi":"10.1016/j.neuropharm.2025.110542","DOIUrl":null,"url":null,"abstract":"<div><div>Parkinson's disease (PD) is a devastating neurological age-related ailment that causes dysfunction in the motor system, leading to symptoms such as involuntary shaking at rest, muscle stiffness with jerky movements, difficulty with walking, sluggish movement, and issues in sustaining posture. A state of insufficient dopamine in the striatum can be linked to a significant decrease in dopaminergic neurons within the substantia nigra pars compacta. Likewise, the formation of Lewy bodies is a distinctive pathogenic feature of PD. Although contemporary therapeutic strategies for PD focus on preserving dopaminergic neurons or restoring dopamine levels in the brain, it is crucial to recognize that achieving total remission of the illness is still inaccessible. MicroRNAs (miRNAs) are a group of tiny RNAs that do not code for proteins. They play a substantial role in controlling gene expression after the process of transcription. miRNAs have a pivotal role in the underlying pathological mechanisms of various neurodegenerative diseases, including PD. The objective of this research initiative is to create a molecular network in order to identify miRNAs that have significant impacts on the evolution of PD, with the intention of utilising them for instant diagnosis as well as prompt prognosis.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":"278 ","pages":"Article 110542"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390825002485","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Parkinson's disease (PD) is a devastating neurological age-related ailment that causes dysfunction in the motor system, leading to symptoms such as involuntary shaking at rest, muscle stiffness with jerky movements, difficulty with walking, sluggish movement, and issues in sustaining posture. A state of insufficient dopamine in the striatum can be linked to a significant decrease in dopaminergic neurons within the substantia nigra pars compacta. Likewise, the formation of Lewy bodies is a distinctive pathogenic feature of PD. Although contemporary therapeutic strategies for PD focus on preserving dopaminergic neurons or restoring dopamine levels in the brain, it is crucial to recognize that achieving total remission of the illness is still inaccessible. MicroRNAs (miRNAs) are a group of tiny RNAs that do not code for proteins. They play a substantial role in controlling gene expression after the process of transcription. miRNAs have a pivotal role in the underlying pathological mechanisms of various neurodegenerative diseases, including PD. The objective of this research initiative is to create a molecular network in order to identify miRNAs that have significant impacts on the evolution of PD, with the intention of utilising them for instant diagnosis as well as prompt prognosis.
期刊介绍:
Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).